-
Mashup Score: 6Second Chance for Life After Stem Cell Transplant - 1 year(s) ago
For 37 years, Kevin Ganton loved listening to the stories of courage told by residents in the assisted living homes that he owns in Jackson. But when he was diagnosed with non-Hodgkin lymphoma, he would have his own war story to tell. It would involve his tenacious care team at Henry Ford Hospital in Jackson. And later in downtown Detroit, stem cell transplant experts would act as armed special forces in his battle. An outdoor sportsman who loves to travel, Kevin was nearing retirement, the greatest time
Source: www.henryford.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Association of Obesity and Type 2 Diabetes with Non-Hodgkin Lymphoma: The Multiethnic Cohort - 2 year(s) ago
AbstractBackground:. Given the role of the immune system in non-Hodgkin lymphoma (NHL) etiology, obesity and type 2 diabetes (T2D) may impact NHL development. We examined the association of body mass index (BMI) and T2D with NHL in the multiethnic cohort (MEC).Methods:. The MEC recruited >215,000 participants in Hawaii and Los Angeles from five racial/ethnic groups; NHL cases were identified through cancer registry linkages. T2D status, and BMI at age 21 and cohort entry were derived from repeated self-reports; for T2D, Medicare claims were also applied. HRs and 95% confidence intervals (CI) for BMI and T2D as predictors of NHL were determined using Cox regression adjusted for relevant covariates.Results:. Among 192,424 participants, 3,472 (1.8%) with NHL and 68,850 (36%) with T2D after 19.2 ± 6.6 years follow-up, no significant association between T2D and NHL (HR, 1.04; 95% CI, 0.96–1.13) was observed. Stratification by BMI at cohort entry showed a significant association of T2D with
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Maskarinec et al examined the association of #BodyMassIndex and Type-2-Diabetes (T2D) with #NonHodgkinLymphoma in the Multiethnic Cohort and find that excess body weight early in life, not T2D may be a predictor. https://t.co/121i0Qf7bq? https://t.co/jEYErlwgsU
-
-
Mashup Score: 0HIV and Blood Cancers: New Insights | Dr. Antonio Giordano| SHRO - 2 year(s) ago
This blog was originally published in La Voce Di New York by Prof Antonio Giordano, click here to read in Italian. Recent research demonstrates that anti-retroviral (ARV) therapies to HIV patients prevent almost two-thirds of cancers, including Kaposi’s sarcoma and non-Hodgkin lymphoma, a cancer of the lymph nodes. These neoplastic diseases are frequently linked to patients with advanced AIDS or HIV-positive. This finding is very intriguing but larger studies are required to evaluate the use of
Source: www.drantoniogiordano.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Blogpost: "Blood cancers linked to HIV: Insights from recent studies" ARV therapies prevent two-thirds of cancers in HIV patients, including Kaposi's sarcoma. Click here to read: https://t.co/9pPXaQGh1Z #HIV #CancerPrevention #sarcoma #NonHodgkinLymphoma #OncologyResearch
-
-
Mashup Score: 1Non-Hodgkin Lymphoma - Cancer Stat Facts - 2 year(s) ago
Non-Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#NonHodgkinLymphoma is the 8th most common cancer in the United States. There will be about 80,550 new cases diagnosed in 2023. Visit our Cancer Stat Facts sheet to learn more about this disease during #LymphomaAwarenessMonth https://t.co/fkI1stg41n https://t.co/5kq832ToNf
-
-
Mashup Score: 0A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma - 2 year(s) ago
Key Points. Pembrolizumab is effective as consolidative therapy for patients with PTCL in first remission.Pembrolizumab administered after ASCT has an acceptabl
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
A phase 2 study of #Pembrolizumab after autologous #StemCell transplantation in patients with T-cell #NonHodgkinLymphoma 👉https://t.co/hSHeMa4o66 @Blood https://t.co/RzxgbyahGj
-
-
Mashup Score: 4VJHemOnc – The video journal of hematological oncology - 2 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EHA2023 ❘ We had a great interview with @ValentinOrtizMD (@hospitalclinic) about CART19 treatment in NHL and ALL. Stay tuned for the full interview, which will be posted on https://t.co/O9p0vDBrzw 🎥 @EHA_Hematology #NonHodgkinLymphoma #ALLsm #CART https://t.co/K7rzJugPMF https://t.co/gGqti37aEo
-
#EHA2023 ❘ A lovely discussion between Lydia Scarfò (@MyUniSR) and @Othman_Al_Sawaf (@UniCologne) on next-generation BTK inhibitors in #CLL. Stay tuned for the full discussion on https://t.co/O9p0vDBZp4 🎥 @EHA_Hematology #CLLsm #Leukemia #HemOnc https://t.co/S0O2lsLgUo
-
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 2 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EHA2023 ❘ We just spoke with @ValentinOrtizMD (@hospitalclinic) about CART19 treatment in NHL and AML. Stay tuned for the full interview, which will be posted on https://t.co/O9p0vDBrzw @EHA_Hematology #NonHodgkinLymphoma #ALLsm #CART #CaxTx https://t.co/vR2ujugpPt
-
-
Mashup Score: 0
On May 19, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of epcoritamab monotherapy…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Epcoritamab was recently approved by the FDA for patients with R/R #DLBCL and HGBCL. More detail here: 👉https://t.co/nRFjYTtxnr👈 #LYMsm #Lymphoma #NonHodgkinLymphoma #HemOnc
-
-
Mashup Score: 1
On May 19, 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the use of epcoritamab monotherapy…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
On May 19th, the FDA approved epcoritamab in R/R #DLBCL and HGBCL. Read about the details of the approval here: ➡️ https://t.co/iyvMC1x9oy #LYMsm #Lymphoma #NonHodgkinLymphoma #HemOnc
-
-
Mashup Score: 0
According to findings from the POLARIX trial, polatuzumab vedotin plus DA-EPCH-R infusional chemotherapy yielded safe and effective results among patients with aggressive B-cell non-Hodgkin lymphoma.
Source: HMP Global Learning NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In recent #Hematology news, the POLARIX trial found that polatuzumab vedotin plus DA-EPCH-R #chemotherapy was safe and effective among patients with aggressive B-cell #nonHodgkinLymphoma. Click the link to learn more about Dr Ryan Lynch’s research! https://t.co/TlwVJ0yxny https://t.co/PcUYJXdgf1
-
Kevin Ganton's bothersome neck pain led to a diagnosis of Stage 4 large B-cell, #nonHodgkin #lymphoma with treatment including stem cell therapy - and a triumphant story to tell: https://t.co/BcEbSMCE0Y https://t.co/sLZuLzivuX